Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls

Area of Science:

• Hepatology
• Virology
• Pediatric Gastroenterology

Background:

• Chronic hepatitis B (CH-B) affects children worldwide.
• Interferon alpha (IFN) is a treatment option for CH-B.
• Understanding the long-term virological outcomes of IFN treatment in pediatric CH-B is crucial.

Purpose of the Study:

• To compare the virological outcomes of CH-B in children treated with IFN versus those who received no treatment.
• To evaluate the long-term efficacy of IFN in achieving HBeAg and HBsAg clearance in pediatric CH-B patients.
• To identify factors influencing treatment response, such as baseline ALT levels.

Main Methods:

• A cohort study involving 74 children with CH-B, divided into IFN-treated and control groups.
• Matching of control participants to treated children based on baseline ALT, sex, and age.
• Kaplan-Meier analysis to estimate time to hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) clearance.

Main Results:

• No significant difference in overall HBeAg and HBsAg loss rates between IFN-treated and control groups.
• 7-year cumulative HBeAg clearance rates were 47.5% in the treated group vs. 33.5% in controls (not significant).
• Elevated baseline ALT levels significantly improved long-term HBeAg seroconversion in treated children (P = 0.01).

Conclusions:

• Overall long-term virological outcomes in pediatric CH-B do not significantly differ between IFN treatment and no treatment.
• IFN treatment offers a significant benefit for long-term HBeAg seroconversion in children with higher baseline ALT levels.
• Further research may explore personalized treatment strategies based on baseline characteristics.